US SEC Filings Daily Market Digest — October 14, 2026

13-10-2026

Avricore Health Inc. furnished a Form 6-K for September 2026 attaching a news release dated September 1, 2026 announcing that its HealthTab™ programme has expanded nationally across England. The filing itself contains no quantitative financial results, amounts, or period-over-period comparisons; the substantive content is limited to the expansion announcement referenced in the exhibit list.

• · Exhibit 1 is a news release titled 'HealthTab™ Programme Expands Nationally Across England', dated September 01, 2026
• · The filing is a Form 6-K for the month of September 2026, Commission File Number 000-51848
• · The registrant is a foreign private issuer that files Form 20-F (not Form 40-F) and has principal offices in Vancouver, BC
• · Filing was signed October 09, 2026 by CFO Kiki Smith, roughly five weeks after the underlying news release

13-10-2026

Braskem S.A. furnished a Form 6-K dated October 2026 (signed October 9, 2026) disclosing Article 11 (CVM Instruction #44/2021) trading of its securities by related persons in September 2026, including Group and Related Persons, Controlling Shareholders, the Board of Directors, Management, and the Fiscal Council, plus Technical or Advisory Bodies. The filing reports routine insider transactions and holdings: a 250 Class A Preferred Share purchase by the Board-related persons, small Management trades, and balances such as 438,761,574 and 123,055,912 shares in the reported categories. No financial results, guidance, or operational performance figures are disclosed.

• · Filing is a Form 6-K under Article 11 of CVM Instruction #44/2021 covering insider trading disclosure for September 2026
• · Filer checks Form 20-F as its annual report type and is not furnishing the information under Rule 12g3-2(b)
• · Several categories report no transactions during the month, indicating limited insider activity

13-10-2026

Brookfield Infrastructure Partners L.P. and Brookfield Infrastructure Corporation (BIPC) filed a Form 6-K for October 2026 furnishing Exhibit 99.1, a press release dated October 9, 2026. The filing itself is a cover document with signatures and an exhibit list; it contains no financial figures, operating metrics, or substantive disclosures in the body text. The substance of any announcement resides in the referenced press release, which was not included in the provided content.

• · Filing made under Form 20-F designation (registrant checked Form 20-F, not Form 40-F)
• · Principal executive offices listed as 73 Front Street, Fifth Floor, Hamilton, Bermuda and 250 Vesey Street, 15th Floor, New York, NY
• · Commission File Number 001-33632 (Partnership) and 000-56727 (Corporation)
• · Exhibit 99.1 is a press release dated October 9, 2026; its content is not included in the filing text provided

13-10-2026

Brookfield Renewable Partners L.P. (BEPJ) furnished a Form 6-K for October 2026 that attaches only Exhibit 99.1, a press release dated October 9, 2026. The cover page and signature block identify the registrant, a Bermuda-based foreign private issuer, and signatory James Bodi (President of the general partner). The filing body contains no financial figures, percentages, or operating metrics, so the substantive content resides in the unattached-in-text press release.

• · Filing references Exhibit 99.1, a press release dated October 9, 2026, but the press release text is not included in the provided content
• · Registrant is a foreign private issuer filing a 20-F annual report (Form 20-F box checked), Commission File Number 001-35530
• · Filing date (October 13, 2026) differs from the signature date (October 9, 2026)

13-10-2026

CL Workshop Group Limited (Nasdaq-listed, Macau-based) received notice from Nasdaq on September 16, 2026 that it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), closing the deficiency matter first disclosed May 8, 2026. Compliance was based on ADS closing bids at or above $1.00 for 10 consecutive business days, September 1 to September 15, 2026. The filing contains no financial results, revenue, or other quantitative operating data.

• · Original Nasdaq deficiency letter was dated May 6, 2026 and disclosed May 8, 2026
• · Filing is a Form 6-K for the month of October 2026, signed October 9, 2026
• · Company incorporates this report by reference into Form F-3 (File No. 333-297543) and Form S-8 (Registration No. 333-299186)

13-10-2026

CytoMed Therapeutics Limited received a Nasdaq notification on October 6, 2026, stating it is not in compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), after its ordinary shares traded below $1.00 for 30 consecutive business days from August 24, 2026 to October 5, 2026. The company has been granted a 180-calendar-day compliance period until April 5, 2027, to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days; the notice does not immediately affect listing or trading.

• · Nasdaq listing rule cited: 5550(a)(2), minimum bid price of $1.00 per share
• · Notification letter received October 6, 2026; press release issued October 9, 2026 (Exhibit 99.1)
• · If the company cannot cure by April 5, 2027, it may qualify for a second compliance period if it meets market value of publicly held shares and other initial listing standards for the Nasdaq Capital Market, and provides written notice of intent to cure, potentially via reverse stock split
• · Company states it is actively monitoring the bid price and considering all available options

13-10-2026

Vale S.A. issued a clarification note on October 9, 2026 responding to media reports and social media statements about the July 22, 2026 Board sanction removing former Vice-Chairman Marcelo Gasparino da Silva for the deliberate leak of confidential June 19, 2026 Board meeting information. The company says an external investigation confirmed the leak, that Gasparino admitted sending a draft vote and statement to a market analyst, that the CVM has opened an administrative proceeding against him, and that Vale has served him a notice to cease disseminating statements and intends to pursue civil and criminal remedies. The filing also includes routine governance disclosures (politically exposed person declarations, shareholder meeting quorums, board resignations and appointments), with no financial performance figures reported.

• · Gasparino's removal was effective upon his resignation, which took effect August 1, 2026; the removal itself would have required shareholder confirmation at an Extraordinary General Meeting.
• · A Previ-requested Extraordinary General Meeting on removing Chairman Daniel Stieler was called following a June 11, 2026 request by a shareholder holding 7.01% of capital.
• · Stieler resigned as Chairman on July 6, 2026 and Wilfred Bruijn was elected interim Chairman on July 14, 2026.
• · The investigation found Gasparino's leaked vote was sent to more than one third party outside the company, and that he shared a summary of June 19 Board resolutions before the July 22 EGM notice was published.
• · Gasparino did not attend the July 22 Board meeting and declined repeated opportunities to be interviewed during the investigation.
• · The company filed an updated Reference Form (item 7.8) on October 9, 2026 with additional disclosure on these facts.
• · Vale says it will continue to provide information requested by the CVM and will pursue criminal measures alongside civil remedies.

13-10-2026

Vizsla Silver Corp. (VZLA) furnished a Form 6-K for October 2026 under the Securities Exchange Act, attaching three exhibits: a news release dated October 9, 2026, a report of voting results, and a 2026 Shareholder Rights Plan. The filing itself contains no financial figures, and the substantive content is contained in the attached exhibits, which are not reproduced in the filing text provided.

• · Filed as a Form 40-F filer (Canadian multijurisdictional disclosure system), Commission File Number 001-41225
• · Exhibit 99.1 is a news release dated October 9, 2026; Exhibit 99.2 is a report of voting results, likely from a shareholder meeting
• · Exhibit 99.3 is a 2026 Shareholder Rights Plan, which is typically an anti-takeover mechanism that can be material to shareholder rights and potential takeover dynamics

13-10-2026

Starry Sea Acquisition Corp (SSEAR) disclosed that its Extraordinary General Meeting, originally set for October 9, 2026, has been postponed to October 19, 2026 to allow more time for shareholder engagement. As of the October 7, 2026 redemption tabulation, 4,281,993 public shares had been submitted for redemption, leaving 1,468,007 public shares outstanding. The company is seeking to reverse approximately 350,174 redemption requests, which would bring outstanding public shares to at least 1,818,181 and keep the monthly extension contribution at the $60,000 cap.

• · Extraordinary General Meeting postponed from 10:00 a.m. ET on October 9, 2026 to 9:00 a.m. ET on October 19, 2026
• · Approximately 74.5% of public shares (4,281,993 of 5,750,000 implied) were submitted for redemption by the October 7, 2026 deadline, based on the post-redemption outstanding count
• · Company is soliciting reversal of about 350,174 redemption requests to reach at least 1,818,181 public shares outstanding
• · Filing is a soliciting material disclosure under Rule 14a-12, not a deal announcement

13-10-2026

Super League Enterprise filed a supplement (DEFA14A) to its September 25, 2026 definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held October 16, 2026. The supplement clarifies that the two Metaplanet Director Designees not yet identified will be determined by Metaplanet after the closing of the Metaplanet Transaction, rather than before. The Board's voting recommendations (FOR Proposal No. 1 Class III director nominees and FOR Proposals 2 through 7) are unchanged.

• · Metaplanet will designate the Chair of the Super League Board for so long as it is entitled to designate and nominate directors, with the Chair to be determined prior to the Closing
• · Metaplanet Director Designees serve until the next annual meeting or until successors are duly elected
• · The Board fills director vacancies using its authority under the Bylaws, appointing Metaplanet Director Designees to replace resigning directors

13-10-2026

Non Invasive Monitoring Systems Inc (NIMU) filed an amended S-1 registration statement dated October 13, 2026, covering financial data for the six months ended June 30, 2026 and the fiscal years through July 31, 2025. The filing discloses a pending merger agreement with Gravitics, Inc. (dated March 6, 2026, with an amendment referenced for August 5, 2026) and continued reliance on related-party promissory note financing from Frost Gamma Investments Trust and Dr. Jane Hsiao. The extracted text is primarily XBRL tagging metadata, so specific reported dollar amounts and period-over-period performance figures could not be reliably extracted.

• · Merger agreement between NIMU and Gravitics, Inc. dated March 6, 2026, with an amendment referenced as of August 5, 2026
• · Subsequent event dated July 27, 2026 disclosed in the filing
• · Convertible promissory note purchase agreement dated June 24, 2026 with a range of principal amounts referenced
• · New promissory note agreement with Dr. Jane Hsiao dated May 7, 2026
• · Multiple related-party promissory notes with Frost Gamma Investments Trust and Dr. Jane Hsiao, including notes dated 2021 through 2025 and a subsequent-event note dated January 5, 2026
• · Series Seed and Series A redeemable convertible preferred stock tied to Gravitics, Inc. are referenced in equity statements

13-10-2026

NuvOx Therapeutics, Inc. (NYSE American listing sought under symbol NUOX) filed Amendment No. 2 to its Form S-1 registration statement for an initial public offering of 2,860,000 shares of common stock, with an anticipated price range of $6.00 to $8.00 per share and a 45-day over-allotment option for up to 429,000 additional shares. The clinical-stage biopharmaceutical company is developing NanO2, an intravenously administered oxygen therapeutic whose API is dodecafluoropentane, for hypoxia-related diseases. The offering is contingent on NYSE American listing approval, and the filing discloses no revenue, earnings, or other financial performance figures in the excerpt provided.

• · Registration No. 333-297520; Amendment No. 2 to Form S-1, dated October 9, 2026 and filed October 13, 2026
• · Company is an emerging growth company and smaller reporting company electing reduced reporting requirements
• · Underwriter/representative is ThinkEquity; underwriting discount and proceeds table left blank pending pricing
• · Risk Factors begin on page 17; Underwriting section on page 165
• · NanO2 converts from emulsified liquid to gas at body temperature, delivering more oxygen than in liquid state
• · Target indications include diseases where hypoxia plays a critical role; glossary references GBM, TBI, ARDS, ALS, and MI

13-10-2026

SPACCircle Acquisition Corp., a Cayman Islands blank-check company, filed an amended S-1 registration statement for an IPO of 15,000,000 units, each containing one Class A ordinary share, one warrant exercisable at $11.50, and one share right entitling the holder to one-third of a Class A ordinary share upon completion of a business combination. A simultaneous private placement of 254,090 units is planned, and the sponsor paid $25,000 for 5,750,000 founder shares, of which up to 750,000 are subject to forfeiture depending on over-allotment exercise. The filing is a blank-check structure with no operating business and no proceeds yet deployed, and it contains no reported financial performance results, so the sentiment is neutral.

• · Separate trading of shares, warrants and share rights is prohibited until a Form 8-K with an audited balance sheet reflecting receipt of gross proceeds is filed.
• · Warrants become exercisable 30 days after the initial business combination and expire five years after completion or earlier upon redemption or liquidation.
• · Warrants are redeemable at $0.01 each if the closing price is at least $18.00 for 20 of 30 trading days, starting 150 days after the business combination.
• · Only Class B holders vote on director appointment/removal before the business combination and on any continuation outside the Cayman Islands.
• · Share rights expire worthless if no business combination is completed and public shares are redeemed from the trust account.
• · The filing references a registration number 333-298956 and an earlier signature date of October 9, 2026, versus the October 13, 2026 filing date.

13-10-2026

VME Companies, Inc. filed an amended S-1 registration statement (S-1/A) in connection with a proposed Nasdaq IPO. Upon completion, Vinson-Shea Holdings, Ltd. (controlled by CEO Michael Thomas) and Kole & Marlee Holdings, Ltd. (controlled by COO Kuoh Lee) will hold a majority of voting power, making VME a 'controlled company' that will rely on exemptions from certain Nasdaq governance requirements. The filing also discloses litigation with aggregate potential exposure of approximately $17 million, partially offset by approximately $26.5 million in pending claims and counterclaims, a mixed risk picture for prospective investors.

• · Post-IPO, the two controlling holding companies will hold a majority of voting power, allowing exemption from Nasdaq requirements for a majority-independent board and fully independent compensation and nominating committees
• · Controlling stockholders may take actions (dividends, related-party transactions, corporate governance) that diverge from other shareholders' interests
• · The company has no current securities analyst coverage, and future downgrades or lack of coverage could pressure the share price
• · Company relies on patents and IP, but notes enforcement is difficult and litigation may take years; patents may be invalidated by the USPTO or foreign equivalents
• · Company faces risk from new technologies by competitors that could displace its products and services
• · Potential exposure from tax audits and disputes in multiple jurisdictions could materially increase worldwide taxes
• · Accounting estimates and possible restatements could materially affect reported financial condition

13-10-2026

Health In Tech, Inc. (HIT), a Nevada AI-enabled insurance technology marketplace for stop-loss policies, filed Amendment No. 1 to its Form S-3 registration statement to register resale of shares issuable under a Standby Equity Purchase Agreement (SEPA) with Yorkville. The SEPA provides up to $20.0 million of Class A common stock sales at the Company's option, with up to $15.0 million of pre-paid advances funded via Convertible Notes. The filing is a resale registration with no obligation on the Company to draw funds, and it introduces potential dilution through conversion and advance shares.

• · Yorkville may purchase Advance Shares at 97% of the lowest daily VWAP in the Pricing Period, creating a built-in discount that can pressure the share price.
• · Share count reduces by one-third for each trading day with an excluded VWAP, which can change proceeds for a given Advance.
• · Advance Maximum Amount is capped at 100% of the five-day average daily Nasdaq trading volume, limiting sizes relative to liquidity.
• · The Company is under no obligation to sell shares or draw advances, so the $20.0M commitment is an option rather than committed funding.
• · The Company holds an 85.72% economic interest and 28.58% voting interest in HITChain Inc., incorporated January 2, 2026, indicating a controlled but economically diluted subsidiary structure.
• · Anchor 36, LLC and HITRix, LLC were formed as wholly-owned subsidiaries in September 2026.
• · The company is an emerging growth company and smaller reporting company, permitting reduced disclosure and two years of audited financials.

14-10-2026

Verastem Oncology announced that Michael P. Bailey will succeed Daniel Paterson as President and CEO effective January 1, 2027, as part of a planned succession plan. Paterson, who served as CEO since 2023 and with the company since 2011 (15-year tenure per the release), will retire, remain on the Board, and serve as an advisor. The company highlighted commercial progress for AVMAPKI FAKZYNJA CO-PACK and clinical advancement of VS-7375, though the release contains no financial results or quantitative performance figures.

• · Bailey has served on Verastem's Board since May 2026 and previously led AVEO as CEO from January 2015, including the FOTIVDA approval and launch in 2021
• · VS-7375 is in registration-directed Phase 2 trials (TARGET-D 201 in pancreatic, 202 in NSCLC, 203 in colorectal) and a Phase 3 trial in first-line metastatic pancreatic cancer is expected to begin later in 2026
• · VS-7375 holds FDA Fast Track Designation for KRAS G12D-mutated PDAC (first-line and previously treated) and previously treated NSCLC
• · AVMAPKI FAKZYNJA CO-PACK received accelerated FDA approval on May 8, 2025 for KRAS-mutated recurrent LGSOC; continued approval may depend on a confirmatory trial
• · Paterson will remain on the Board and as an advisor after stepping down as CEO

14-10-2026

Fearless Solutions, LLC dba Best Invest (San Antonio, TX) filed a Form 13F-HR for the period ended September 30, 2026, disclosing 143 holdings with a reported total portfolio value of approximately $196.5 billion (196,522,046 thousand dollars per the cover page's reported table value). The portfolio is concentrated in large-cap technology and ETFs, with Apple, Alphabet, Amazon, and Blackstone among the largest individual positions. Because the filing covers holdings only, it contains no period-over-period performance comparison, and it does not disclose changes from the prior quarter.

• · Largest disclosed positions by value are Apple (~$10.1B), Amazon (~$5.0B), Blackstone (~$3.8B), and Alphabet Class A (~$3.3B), with ETFs forming a substantial share of the holdings.
• · Holdings include a broad mix of individual equities and exchange-traded funds spanning equity, fixed income, commodity, and sector exposures.
• · The filing is signed by Aryn Sands as agent, with the report dated October 14, 2026.

14-10-2026

Focus Financial Network, Inc. (CIK 0002010942, Minneapolis, MN) filed a Form 13F-HR on October 14, 2026 for the quarter ended September 30, 2026, disclosing its equity and fund holdings in an institutional information table. The excerpt provided is truncated, so only a partial list of positions is visible; the largest visible positions include Amazon (289,543 shares), Apple (339,213 shares), and Alphabet Class A (88,182 shares). No period-over-period comparison is available in the filing excerpt, so performance trends cannot be assessed.

• · Filing is for the reporting period ended September 30, 2026, filed October 14, 2026 under SEC file number 028-24075.
• · Holdings are reported with sole investment discretion and no shared or other-manager voting authority in the visible rows.
• · The visible portion of the information table includes numerous ETF positions across multiple issuers (iShares/BlackRock, First Trust, AIM ETF Products Trust, Fidelity, Dimensional), indicating a diversified, index- and ETF-heavy portfolio.
• · Visible convertible note positions (Affirm, Akamai, DexCom, DoorDash) are small in face value (≈$10,000–$12,000 thousand principal per the table).
• · The information table is truncated in the provided excerpt; total portfolio value, total position count, and any position changes versus the prior quarter cannot be determined from this content.

14-10-2026

Roberts Wealth Advisors, LLC (Palo Alto, CA; SEC file no. 028-21375) filed a Form 13F-HR on October 14, 2026 for the quarter ended September 30, 2026, reporting 108 holdings with a total reported value of approximately $445.4 million (445,394,713 in thousands per the information table convention). The portfolio is concentrated in large-cap technology and mega-cap names, led by Apple, Microsoft, Alphabet, Amazon, and Nvidia-linked exposure, alongside substantial positions in broad-market and sector ETFs. Holdings in individual stocks and funds are reported as sole-discretion positions with no shared or other-manager voting authority disclosed.

• · Reporting period ends September 30, 2026; filing made October 14, 2026, within the 45-day deadline.
• · Filer SEC file number is 028-21375; CIK 0001885319; EIN 85-0955391; principal office in Palo Alto, CA.
• · Portfolio includes a large allocation to fixed-income and cash-like ETFs (J.P. Morgan ultra-short and short-duration funds, Schwab US treasury and municipal exposures), indicating a defensive/liquidity-oriented sleeve alongside growth equities.
• · All positions are reported with SOLE investment discretion; no shared or other-manager authority is disclosed.
• · Largest single-stock positions by reported value include Apple (~$29.9M), Microsoft (~$17.6M), Alphabet Class C (~$22.8M), and Amazon (~$13.2M); the Alphabet Class C line appears larger than Class A in value.
• · Filing contains no prior-period comparison, so quarter-over-quarter position changes cannot be assessed from this document alone.

14-10-2026

ASK Capital Investment Managers, LLC (Amarillo, TX; SEC file no. 028-27226) filed its Form 13F-HR for the quarter ended September 30, 2026, reporting 28 equity and ETF positions with a total reported market value of approximately $97.08 million. The portfolio is concentrated in large-cap technology and consumer names, with Apple, Walmart, Microsoft, and Alphabet as the largest holdings, while the filing does not provide prior-quarter figures, so no period-over-period change can be calculated.

• · Filing covers the period ended September 30, 2026, and was filed October 14, 2026; the filing is a holdings report only and includes no prior-period comparison.
• · All 28 positions are reported as sole investment discretion (SOLE), with no shared or other-manager discretion reported.
• · Concentration: the top five holdings by value (Apple, Alphabet, AbbVie, Microsoft, Walmart) account for roughly 35% of reported portfolio value.
• · Energy exposure is present through Chevron, Phillips 66, Valero Energy, and NextEra Energy (utility); Texas Pacific Land, based in Texas, is also held.
• · Old Republic International Corp. carries a large share count (86,670 shares) but a modest dollar value (about $3.23M), implying a relatively low per-share price versus other holdings.
• · Valero Energy position is small (1,000 shares, about $0.39M) relative to the rest of the energy sleeve.

14-10-2026

Transocean Ltd. (RIG) has called an extraordinary general meeting for November 24, 2026 to seek shareholder approval for its Business Combination with Valaris Limited under a February 9, 2026 Business Combination Agreement. Each Valaris share would be exchanged for 15.235 Transocean shares, with Transocean shareholders and Valaris shareholders expected to own approximately 53% and 47% of the combined company, respectively, on a fully diluted basis. Shareholder approval of the share issuance resolutions and the NYSE 20% share issuance proposal is a condition to completing the transaction.

• · Extraordinary general meeting scheduled for November 24, 2026 at 3:00 p.m. Swiss time at Steinhausen, Switzerland
• · Proxy voting deadline is 4:00 p.m. Eastern Time on November 23, 2026; record date for voting is November 9, 2026
• · Transocean Board unanimously recommends voting FOR all Transocean Resolutions
• · Unless the ordinary share capital increase, capital band, and NYSE 20% share issuance proposal are all approved, none of the resolutions or director elections take effect
• · Six agenda items include share issuances, an NYSE 20% issuance proposal, two director/committee election resolutions, and removal of obsolete Article 38 from the Articles of Association
• · Shareholder approval is a condition to completing the Business Combination

14-10-2026

Pharming presented positive Phase II topline data for leniolisib in genetically identifiable primary immunodeficiencies with immune dysregulation at ESID 2026 (Maastricht, October 14-17, 2026). Mean spleen volume fell 26.4% (10 of 11 evaluable participants improved) and mean lymph node index lesion size fell 33.7% (all four evaluable), with 8.0% mean DLCO improvement among participants with impaired gas exchange. However, the study was small (13 participants, single-arm, open-label), one participant discontinued early due to acute hepatitis, and two serious adverse events occurred (deemed unrelated to leniolisib). Results are investigational and lack statistical significance testing.

• · One participant with portal hypertension discontinued early due to acute hepatitis
• · Two participants experienced serious adverse events deemed unrelated to leniolisib
• · Liver stiffness improved in 2 of 3 participants with elevated baseline stiffness (small sample)
• · Study is single-arm, open-label, intra-patient dose-escalation with 13 participants; no statistical significance reported
• · Safety and efficacy of leniolisib not established for investigational uses beyond APDS
• · CVID Phase II topline results expected in November 2026
• · Data presented as a late-breaking abstract poster

14-10-2026

Banco Santander, S.A. announced its decision to carry out the optional early redemption of all outstanding 4.750% Non-Step-Up Non-Cumulative Contingent Convertible Perpetual Preferred Tier 1 Securities (CoCos, ISIN US05971KAH23), with a total nominal amount of USD 298.4 Million. The redemption, authorised by the European Central Bank, will take place on the first optional early redemption date, the distribution payment date of 12 November 2026, and the decision is irrevocable. The filing contains no period-over-period financial results, so no balanced performance comparison applies.

• · Redemption will be effected on 12 November 2026, the first optional early redemption date and distribution payment date
• · Redemption price equals outstanding nominal amount (liquidation preference) plus accrued but unpaid distributions to but excluding 12 November 2026
• · The CoCos were issued under a prospectus supplement dated 6 May 2021 and Form F-3 Registration Statement (File No. 333-238243)
• · The Issuer's decision to exercise the redemption right is irrevocable

14-10-2026

Evotec SE filed a Form 6-K furnishing Exhibit 99.1, an ad hoc announcement issued October 13, 2026, reporting preliminary nine-month 2026 results above market expectations and reaffirming full-year 2026 guidance. The filing itself contains only the cover page, exhibit index, and signature; the specific financial figures are not included in the text provided and would be found in Exhibit 99.1.

• · Preliminary nine-month 2026 results were characterized as above market expectations, per the exhibit title.
• · Full-year 2026 guidance was reaffirmed, not raised or lowered.
• · The announcement was issued as an ad hoc announcement on October 13, 2026, one day before this filing date.
• · Exhibit 99.1 is required to obtain the actual revenue, earnings, and other quantitative figures; these are not present in the provided filing text.

14-10-2026

SK hynix Inc. filed a Form 6-K on October 14, 2026 announcing a conference call on October 28, 2026 at 9:00 a.m. Seoul time to discuss its 2026 third-quarter earnings results, followed by a Q&A session. The call will be webcast in Korean and English, with an archive available on the company's Investor Relations website, and materials will be posted there on the day of the call.

• · Call date and time: October 28, 2026, 9:00 a.m. (Seoul Time)
• · Call format: audio conference call with real-time webcast in Korean and English simultaneously
• · Participants: investors and press
• · Call materials to be posted on the IR website on October 28, 2026 (Seoul time)
• · Filing is made by the company as a foreign private issuer (Form 20-F filer), with the report signed by Head of Investor Relations

14-10-2026

HDFC Bank Limited furnished a Form 6-K for October 2026 attaching an earnings call transcript (Exhibit 99) covering its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The filing itself contains no numerical financial figures, so performance details cannot be verified from the document provided and sentiment cannot be assessed on the substance of the results.

• · Filing is a Form 6-K under Rule 13a-16 / 15d-16 for the month of October 2026, signed October 13, 2026
• · Registrant files annual reports on Form 20-F
• · Exhibit 99 is an earnings call transcript for the quarter and half-year ended September 30, 2026, with results described as unaudited standalone and consolidated
• · Filing content provided is limited to the cover page, signature block, and exhibit index; the exhibit's financial figures are not included

14-10-2026

FortuneX Acquisition Corporation, a Cayman Islands SPAC, and its Merger Sub entered into a First Amendment dated October 13, 2026 to its September 18, 2026 Business Combination Agreement with WT Realty Group Inc. The amendment fixes the Aggregate Merger Consideration at 52,500,000 shares of PubCo Common Stock, implying an agreed equity value of $525,000,000 at a $10.00 reference price per share, with no adjustment for cash, indebtedness, working capital, escrow or holdback. The filing is an administrative-style amendment; it does not disclose a change in deal status, financing outcome, or closing timeline.

• · Reference price per share is $10.00, and 52,500,000 shares x $10.00 reconciles to the $525,000,000 agreed equity value
• · Consideration is fixed and not subject to cash, net debt, working capital, purchase price adjustment, escrow or holdback
• · Amendment is made under Section 11.2 of the Business Combination Agreement and governed by Delaware law
• · Amendment becomes effective upon delivery of executed counterparts or signature pages from all parties

14-10-2026

SK Telecom issued a clarification on October 14, 2026, responding to an October 13 Electronic Times report that the company was seeking an additional 5 GW of overseas AI data center capacity for an Asian hub. The company stated that, beyond what it already disclosed in its June 30, 2026 Fair Disclosure filing (a phased AI data center buildout targeting 15 GW total mid- to long-term capacity under review), there are no specific plans regarding the media report's claims, including securing 5 GW of overseas capacity.

• · The company clarified that the June 30, 2026 disclosure (Future Business and Management Plan) remains the only publicly disclosed basis for its AI data center plans
• · The filing is a Form 6-K for the month of October 2026, furnished under Rule 13a-16 by a Form 20-F filer

14-10-2026

Mariselle a.s., its parent Czechoslovak Group a.s. (CSG), and Group Investment Manager Miroslav Holan filed a Schedule 13D reporting beneficial ownership of 15,356,219 MDA Space Ltd. common shares, approximately 9.5% of shares outstanding, acquired on October 13, 2026 via physical settlement of a Share Forward Transaction with Morgan Stanley Europe SE at an average price of CAD 42.6903 per share. The filing states the position was taken for investment purposes, and the reporting persons reserved the right to take a range of future actions, including proposals on capital allocation, ownership structure, or a sale of the issuer in whole or part.

• · Investment Canada Act approval was obtained on October 8, 2026, enabling physical settlement
• · The physical settlement option was exercised on October 9, 2026, with settlement occurring October 13, 2026
• · Settlement was funded with working capital of Czechoslovak Group a.s.
• · The Share Forward Transaction was originally cash-settled only unless Investment Canada Act approval was obtained
• · Shares are listed on the NYSE and TSX
• · The filing notes no contracts or arrangements with other persons regarding the issuer's securities, and no other person has rights to dividends or sale proceeds

14-10-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on October 14, 2026, furnishing Exhibit 99.1, a press release announcing that its subsidiary RAD has received an order for seven ROSA units from another municipal customer. The filing itself contains no financial results, dollar amounts, or quantitative performance data; the material is furnished under Item 8.01 and expressly not deemed filed under Section 18 of the Exchange Act.

• · The order is from a municipal customer, described as an addition to RAD's existing municipal customer base
• · The filing was made under Item 8.01 (Other Events) and Item 9.01 (Exhibits), with the press release attached as Exhibit 99.1
• · The company's principal executive offices are in Ferndale, Michigan, and its trading symbols are not listed on a registered exchange per the cover page

14-10-2026

Nomura Holdings disclosed its monthly treasury share disposition and share repurchase report for the reporting month ending September 2026. The only disposition was 68 shares sold for JPY 109,038 to satisfy purchases of less-than-a-full-unit shares, with no cancellations, merger transfers, stock acquisition right exercises or RSU deliveries. Under the January 30, 2026 Board authorization (up to 100,000,000 shares and JPY 60,000,000,000, running February 17 to September 30, 2026), no repurchases were made during the month, leaving cumulative progress at 46.9% of shares and 100.0% of the amount authorized.

• · No shares were repurchased during September 2026 under the buyback program
• · The buyback authorization period runs from February 17, 2026 to September 30, 2026, excluding ten business days following each quarterly earnings announcement
• · Cumulative repurchases reached 46,861,200 shares, or 46.9% of the 100,000,000-share authorization, while spending essentially the full JPY 60 billion authorized amount
• · No treasury shares were canceled, transferred under mergers or share exchanges, disposed through stock acquisition right exercises, or delivered under the RSU plan during the month

14-10-2026

ASML Holding N.V. reported Q3 2026 total net sales of €11.7 billion and net income of €5.0 billion, as disclosed in Exhibits 99.1 (press release) and 99.2 (presentation) furnished under this Form 6-K dated October 14, 2026. The company guided full-year 2026 total net sales to between €44 billion and €45 billion, with gross margin around 56%. The filing itself contains no explicit period-over-period comparison figures, so the prior-period baseline cannot be assessed from the text provided.

• · Filing incorporates Exhibits 99.1 and 99.3 by reference into multiple Form S-8 registration statements (File Nos. 333-203390, 333-219442, 333-227464, 333-291580)
• · Exhibit 99.3 contains Summary US GAAP Consolidated Financial Statements, which were not included in the provided text
• · Company is a foreign private issuer filing under Form 20-F (annual report) basis

14-10-2026

Valaris Ltd filed a joint proxy statement (DEFM14A) on October 14, 2026 in connection with its proposed Business Combination with Transocean, under which Valaris would become a wholly-owned subsidiary of Transocean and Valaris shareholders would receive Transocean Shares. The filing presents unaudited pro forma combined results showing contract drilling revenues of $3,052 Million for the six months ended June 30, 2026 with net income of $203 Million, versus a pro forma net loss of $3,327 Million and operating loss of $2,048 Million for FY2025, reflecting a mixed earnings picture. Ownership disclosures show BlackRock (11.39%), Famatown Finance (11.28%, party to a shareholder support agreement with Transocean) and Vanguard (9.29%) as the largest Valaris holders.

• · Famatown Finance and affiliates signed a Valaris Shareholder Support Agreement with Transocean on February 9, 2026 agreeing to vote their Valaris Shares in favor of the Business Combination; the agreement does not grant Transocean a voting proxy
• · Valaris shareholders would receive Transocean Shares and be governed by Swiss law and the Transocean Articles if the Business Combination closes
• · If the Business Combination is not consummated, Valaris expects to hold its 2027 Annual General Meeting; shareholder proposals for inclusion in that proxy must be delivered by December 17, 2026
• · Vanguard reported in March 2026 an internal realignment, after which it no longer has or is deemed to have beneficial ownership of the reported shares, and affiliated divisions will report separately
• · Pro forma FY2025 results show a substantial net loss, contrasting with positive pro forma net income in the six months ended June 30, 2026

14-10-2026

Liquidia Corporation entered a global settlement with United Therapeutics that resolves all six pending lawsuits between the companies, with YUTREPIA remaining available for PAH patients. Liquidia will make a net payment of $175 million within 30 business days, plus $145.4 million in two installments of $72.7 million due January 31, 2027 and April 30, 2027, and it has agreed not to appeal the September 30, 2026 Delaware ruling finding claims of the '327 patent valid and infringed, removing the PH-ILD indication from YUTREPIA's label. Preliminary unaudited Q3'26 YUTREPIA net product sales were $222.7 million, with $396.1 million in cash as of September 30, 2026, though the PH-ILD indication removal and loss of Treprostinil Injection promotion represent a loss of commercial scope.

• · Liquidia terminated the promotional agreement tied to Treprostinil Injection and will no longer commercially support the product; commercial rights transfer to Sandoz referenced in forward-looking statements
• · Liquidia submitted a Prior Approval Supplement to remove the PH-ILD indication from YUTREPIA's label and no longer promotes it for PH-ILD, which narrows the addressable market
• · The settlement does not extend to indications other than PAH or to new treprostinil-containing products, and United Therapeutics may assert patents against development programs
• · Company expects to fund payments from YUTREPIA sales and cash on hand and does not expect to need additional financing; a broader update comes on the Q3 2026 earnings call in November
• · The Q3 2026 financial figures are preliminary, unaudited, and not reviewed by the independent auditor

14-10-2026

News Corporation filed an 8-K under Item 8.01 (Other Events) to report ongoing activity under its existing stock repurchase program, which authorizes buybacks of up to $1 billion in aggregate across its Class A and Class B common stock. The filing attaches two Exhibits (99.1 and 99.2) containing the daily transaction disclosures provided to the Australian Securities Exchange, as required under ASX rules. No new authorization, amount change, or specific repurchase volumes or prices are disclosed in the body of this filing.

• · Filing is dated October 14, 2026, with an event date of October 13, 2026
• · Company Class A (NWSA) and Class B (NWS) shares trade on the Nasdaq Global Select Market
• · Daily ASX disclosure of repurchase transactions is required, and the company also reports repurchase activity in quarterly and annual reports

14-10-2026

Greater Cannabis Company, Inc. (GCAN), now named Trafalgar International, Inc., filed Amended and Restated Articles of Incorporation in Florida that eliminate all Series A and Series B preferred conversion rights and create a new Series B Preferred class (1,000 authorized shares) that holds at least 51% of aggregate voting power on a fully diluted basis. The restatement also eliminates Series A's per-share voting multiplier and removes conversion mechanics for both series, leaving holders with no right to receive common stock. The filing does not disclose quantitative financial results, and its effect on existing shareholders' voting influence is significant and non-financial in nature.

• · Series B voting formula requires Series B votes to be recomputed immediately upon any issuance, grant, conversion, or other event affecting other fully diluted votes, so the 51% threshold adjusts dynamically.
• · Protective consent provisions prevent amending the Series B terms, issuing voting securities that impair the 51% entitlement, or effecting a merger that eliminates Series B voting rights without majority Series B consent.
• · Series A Preferred Stock's prior per-share voting multiplier, conversion ratios, anti-dilution protections, and accrued dividend rights are all eliminated without surviving consideration.
• · The company changed its legal name from The Greater Cannabis Company, Inc. to Trafalgar International, Inc. under this restatement.

14-10-2026

Pioneer Acquisition I Corp (Nasdaq: PACH) entered into a definitive Business Combination Agreement with Green AI Cloud, Inc., a Stockholm-based European AI data center operator focused on renewable-powered super compute, valuing Green AI Cloud at a $300 million pre-money equity value and implying a pro forma enterprise value of approximately $525 million assuming no redemptions. Closing is expected in Q2 2027, subject to Pioneer shareholder approval and customary conditions, and Pioneer's board received a fairness opinion; the deal is positive for the SPAC's prospects but carries execution and redemption risk, and the press release contains no reported historical financial results for the target.

• · Target's current portfolio includes live, contracted and planned capacity, with a potential multi-GW development pipeline over time
• · Expected proceeds to fund site development, potential acquisitions and expansion into new markets
• · Transaction approved by both boards; Pioneer obtained a fairness opinion before signing
• · Filing is partly a SPAC-style marketing release with forward-looking statements; no audited Green AI Cloud revenue or profitability figures are disclosed
• · Ticker discrepancy: the body cites Nasdaq: PACH while the subject identifies PACHU (the unit ticker)

14-10-2026

Energy Fuels Inc. (NYSE American: UUUU) filed a prospectus supplement under its existing S-3 shelf registration to sell up to an additional $500 million of common shares through its at-the-market (ATM) program with five sales agents. The Company had already sold approximately $300 million of shares under the prior ATM prospectus supplement dated June 13, 2025. The filing is administrative in nature, establishing capacity for future discretionary equity issuance rather than reporting completed sales or operating results.

• · Registration statement referenced is Form S-3 File No. 333-278193
• · Sales Agreement dated June 13, 2025 covers five sales agents
• · Exhibits filed: Legal Opinion of Dentons LLP (Exhibit 5.1) and consent (Exhibit 23.1)
• · Filing date reported as October 14, 2026, while the report's stated date of earliest event and signature date is October 13, 2026

14-10-2026

Biomea Fusion, Inc. (BMEA) hosted a conference call and live webcast on October 13, 2026 to discuss topline data from its ongoing Phase 1 GLP-131 clinical trial for BMF-650, an investigational next-generation oral small molecule GLP-1 receptor agonist being studied for obesity and metabolic disease. The company furnished a slide presentation (Exhibit 99.1) and a press release announcing Phase 1 results (Exhibit 99.2). The filing contains no quantitative efficacy, safety, or financial figures; the results themselves are located in the exhibits.

• · Filed under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits); Exhibit 99.1 is furnished, not filed, under Section 18 of the Exchange Act
• · Company is an emerging growth company; common stock (BMEA) trades on The Nasdaq Global Select Market
• · Forward-looking statements caution that preliminary or interim trial results may not predict final results

14-10-2026

Integral Technologies, Inc. filed its 10-K for the fiscal year ended June 30, 2026, reporting a net loss of $778,097 versus $713,361 in the prior year, an increase of 9.1%. Total assets rose to $344,131 from $19,901, driven by a $220,723 prepaid investment in Apex North, LLC tied to a proposed acquisition, while the stockholders' deficit widened to $(8,467,110) from $(7,689,013). Results remain weak, with the company still carrying substantial liabilities and cash of only $123,408.

• · Net cash used in operating activities widened to $(163,993) from $(101,968), a 60.8% increase, despite the company relying on $487,500 of new notes payable financing
• · Operating cash flow is insufficient to cover ongoing operating costs, with cash of only $123,408 against total liabilities of $8,811,241
• · Interest expense increased $12,487 primarily due to new promissory notes entered into during the year
• · Interest income of $723 was accrued on the $220,000 advance to Apex North, LLC, which is recorded as a non-current asset
• · Shares outstanding were unchanged at 30,766,923, with no equity issuance during the period
• · Income tax provision was zero in both years, with deferred tax benefits fully offset by valuation allowance changes of $406,000 (FY2026) and $372,000 (FY2025)

14-10-2026

Illumination Acquisition Corp. I (ILLUU), a SPAC, reported net income of $2,005,956 for the three months ended August 31, 2026 and $3,843,507 for the nine months, driven almost entirely by $4,129,285 of interest earned on the $234,129,285 Trust Account. Formation, general and administrative costs were $160,010 for the quarter and $434,055 year-to-date, and the company carries a shareholders' deficit of $(7,278,369) largely due to accretion of Class A shares to redemption value and an $8,050,000 deferred underwriting fee. Because the company's income depends on trust interest rather than operations, results are limited by the absence of any operating business or revenue beyond referral fees.

• · Accumulated deficit of $(7,279,199) and shareholders' deficit of $(7,278,369) reflect accretion of $18,099,487 in the first half of the period, which is a non-cash remeasurement of redeemable shares rather than an operating loss
• · Net income of $3,843,507 for nine months is composed of $4,277,562 in other income against only $434,055 of operating costs, so trust interest accounts for virtually all earnings
• · Only $819,260 of cash equivalents sits outside the Trust Account, against $276,197 of cash used in operations over nine months, indicating limited working capital runway
• · Deferred underwriting fee of $8,050,000 is payable and is a material future obligation on the balance sheet
• · Redemption value of $10.18 per share versus $10.00 initial trust funding implies trust growth from interest income

14-10-2026

Chief Administration Officer Uang Du-Tsuen sold 3,000 Ordinary Shares at $752.00 (~$2.26M). Uang Du-Tsuen holds 838,000 shares after the transaction.

• · Chief Administration Officer Uang Du-Tsuen sold 3,000 Ordinary Shares at $752.00 (~$2.26M)

14-10-2026

Sono Group N.V. has filed an amended Form S-4 registration statement for a proposed redomiciliation from the Netherlands to Delaware, executed through a cross-border merger into Sono Group S.à r.l. (Luxembourg) followed by a conversion into Sono Group, Inc. (Delaware). Shareholders will vote at an extraordinary general meeting on December 11, 2026 on the Redomiciliation Proposal, the Merger Proposal, and a Nasdaq Share Authorization Proposal, with the board unanimously recommending approval of all three. The filing discloses no financial results, and no quantitative financial performance data is presented.

• · Extraordinary general meeting scheduled for December 11, 2026 at 1:00 p.m. CET at DLA Piper offices in Amsterdam; attendance notice deadline and proxy voting deadline is 12:00 p.m. CET on December 4, 2026
• · Record date is November 13, 2026
• · Merger Proposal requires a two-thirds majority; Redomiciliation and Nasdaq Share Authorization proposals require a simple majority, each with at least one-third of issued shares represented
• · Redomiciliation Proposal is conditional on approval of the Merger Proposal; the Nasdaq Share Authorization Proposal is not conditional on the other proposals
• · The Merger Agreement is dated October 5, 2026; shares will be exchanged, and Sono N.V. will cease to exist as a result of the merger
• · Sono Group, Inc. will retain the Class A Common Stock structure referenced in the Nasdaq proposal
• · Filing states that no SEC, U.S. state, Dutch, or Luxembourg regulator has approved or disapproved the transaction or the securities to be issued

14-10-2026

Chief Executive Officer Qiu Wenbin bought 5,800 American Depositary Shares at $3.47 (~$20.1K). Qiu Wenbin holds 1,678,572 shares after the transaction.

• · Chief Executive Officer Qiu Wenbin bought 6,000 American Depositary Shares at $3.34 (~$20K)
• · Chief Executive Officer Qiu Wenbin bought 5,800 American Depositary Shares at $3.47 (~$20.1K)

14-10-2026

BlackRock reported Q3 2026 GAAP diluted EPS of $10.57 (up 25% YoY from $8.43) and as-adjusted diluted EPS of $15.93 (up 38% from $11.55), with revenue up 19% YoY to $7,752 Million and AUM of $15,488,263 Million ($15.5 Trillion). Q3 net inflows were $205,466 Million, with 11% annualized organic base fee growth, though GAAP operating income and net income attributable to BlackRock declined sequentially versus Q2 2026 (operating income down $133 Million; GAAP diluted EPS down $1.62 from $12.19), largely due to a $564 Million noncash contingent consideration charge. Mixed signals include strong growth in ETFs and active flows alongside a 3% decline in Q3 institutional index net flows and the sequential GAAP earnings decline.

• · Net inflows of $135000 Million into iShares ETFs and $66000 Million into active strategies in Q3 2026
• · Institutional index strategies experienced $27444 Million of net outflows in Q3 2026, partially offsetting inflows elsewhere
• · Investment advisory performance fees rose to $630 Million from $516 Million YoY but increased sharply from $305 Million in Q2 2026
• · Effective GAAP tax rate increased to 29.4% from 25.2% YoY
• · Q3 2026 nonoperating income of $353 Million included a $353 Million net gain on investments versus $64 Million a year earlier
• · Q3 2026 included a $564 Million noncash contingent consideration charge versus $93 Million in Q3 2025, which depressed GAAP results
• · Dividend declared at $5.73 per share, unchanged sequentially and up from $5.21 YoY

14-10-2026

Quoin Pharmaceuticals (QNRX) announced that its lead product candidate QRX003 received Orphan Drug Designation in Europe from the European Medicines Agency for treating Peeling Skin Syndrome. The designation provides scientific advice on study protocols, fee reductions, and EU grant access, and would confer 10 years of market exclusivity in Europe if QRX003 is approved. The company plans to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end.

• · Orphan Drug Designation confers scientific advice on study protocols, various fee reductions, and access to EU grants
• · Company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end 2026
• · Filing is furnished under Regulation FD and not deemed filed under Section 18 of the Exchange Act

14-10-2026

Bank of America reported 3Q26 net income of $6.9 billion, or diluted EPS of $0.91, down from $8.3 billion and $1.04 a year earlier, after a $1.2 billion regulatory settlement charge ($0.17 per share). Excluding the charge, adjusted net income was $8.1 billion and adjusted EPS $1.08. Revenue rose 3% YoY to $30.0 billion and net interest income rose 8% to $16.4 billion, while noninterest expense rose $2.4 billion to $19.7 billion and the efficiency ratio widened to 66% (62% adjusted). Results are mixed: Consumer Banking, GWIM and loan growth were strong, while Global Banking investment banking fees fell 11% and Global Markets FICC revenue fell 17%.

• · Regulatory settlement charge of $1.2B ($0.17 per share) drove the reported earnings decline; pretax income fell to $9.0B from $10.4B
• · Consumer Banking average loans and deposits were essentially flat YoY, while credit card loans grew 5%
• · Global Markets FICC revenue fell 17% to $2.6B, while equities rose 11% to $2.5B
• · Global Banking investment banking fees fell 11% YoY, a key drag on the Corporation's revenue mix
• · Efficiency ratio deteriorated to 66% (62% adjusted) from 60% a year earlier, reflecting higher expenses
• · Global Liquidity Sources of $914B and CET1 ratio of 10.9% remain well above regulatory minimums

14-10-2026

Accenture plc filed a Form 8-K under Item 7.01 (Regulation FD Disclosure) and Item 9.01 to furnish its financial presentation for the Investor Day held October 14, 2026 at 8:30 a.m. Eastern Time, webcast on its Investor Relations site. The filing contains no quantitative financial results, guidance, or performance metrics; it serves as a disclosure vehicle for the Investor Day materials (Exhibit 99) and the cover page XBRL (Exhibit 104).

• · Investor Day webcast scheduled for 8:30 a.m. Eastern Time on October 14, 2026, accessible via the Accenture Investor Relations website
• · Financial presentation furnished as Exhibit 99 and expressly not deemed 'filed' under Section 18 of the Exchange Act
• · Class A ordinary shares (ticker ACN) are listed on the New York Stock Exchange
• · Filing signed by Joel Unruch, General Counsel, Corporate Secretary & Chief Risk Officer